 The European Commission EC has granted marketing authorization to Ascendis Pharma ASs NASDAQ: ASND Lonapegsomatropin developed under the name TransCon hGH. The approval for TransCon covers a once-weekly subcutaneous injection for children and adolescents ages 3 to 18 years with growth failure due to growth hormone deficiency GHD. 